SPONTAN® pivotal clinical study completes recruitment and dosing

LTR Pharma has today announced that all patients recruited for its pivotal bioequivalence clinical study of SPONTAN® nasal spray have now received their second and final dose, completing the recruitment and dosing stage of the clinical study. The Study is evaluating the relative bioavailability of SPONTAN, a novel and proprietary PDE5 nasal spray treatment compared […]

Ausbiz | Interview with Lee Rodne

This week, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with Juliette Saly from ausbiz to discuss the Company’s progress in the advancement of rapid treatment for Erectile Dysfunction (ED), SPONTAN®, including the commencement of recruitment for its pivotal bioequivalence study. Take a look:

First patients dosed for SPONTAN® bioequivalence clinical study

LTR Pharma is pleased to announce the commencement of patient dosing in the Company’s pivotal bioequivalence clinical study of SPONTAN® nasal spray. The clinical study will assess the relative bioavailability of SPONTAN, a novel and proprietary PDE5 nasal spray treatment for ED. This first-in-kind nasal spray will be compared to oral administration of Vardenafil, a […]

ASX:LTP Half Year Financial Report

LTR Pharma has today released its Half Year Financial Report for the period ended 31 December 2023. This has been a defining period for the Company, marked by a successful ASX debut on 11 December 2023, and rapid progress towards our pivotal bioequivalence study. Key highlights include:  Successfully completed an oversubscribed IPO. The Company listed […]

Stockhead | ASX stocks striving to inject youthfulness into an aging world population

LTR Pharma’s innovative nasal spray for erectile dysfunction, SPONTAN is featured in a Stockhead article by Nadine McGrath titled “ASX stocks striving to inject youthfulness into an aging world population” The article highlights the investment opportunities in ASX-listed companies that are addressing issues associated with longevity and the ageing population. “LTP executive director Lee Rodne […]

Clinical Trials Arena | LTR Pharma begins recruitment in study of nasal spray for ED

News that LTR Pharma’s pivotal clinical trial is set to begin has been reported in Clinical Trials Arena. An excerpt: “The trial will take place in Sydney, Australia, in partnership with Southern Star Research and Scientia Clinical Research. It will be conducted under the supervision of staff from Scientia Clinical Research, while Southern Star Research will […]

BNNBreaking | Revolutionary Nasal Spray for Erectile Dysfunction: SPONTAN® Clinical Trial Begins

BNN Breaking has published the news that LTR Pharma has initiated enrolment of patients for its pivotal bioequivalence clinical trial of the nasal spray treatment, SPONTAN®. An excerpt: “The implications of SPONTAN®’s success extend far beyond the realm of erectile dysfunction. A positive outcome from the trial could set the stage for regulatory approval from heavyweights […]

Stockhead | LTR Pharma firms up study for erectile dysfunction with patient recruitment

LTR Pharma has been featured in Stockhead following the announcement that patient recruitment for its pivotal clinical study of SPONTAN® has opened. An excerpt: “The global ED market is forecast to increase to US$5.94 billion by 2028, growing at a CAGR of 7.1%. With such strong demand for effective ED treatments, LTP hit the Aussie bourse […]